Q2 2026 saw 11% revenue growth to $114.4M, with exome/genome revenue up 17% and volumes up 32% year-over-year. Adjusted gross margin was 70%, and adjusted net income returned to positive territory. Full-year guidance was reiterated, and coverage expanded across Medicaid and commercial payers.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.